Skip to main content
Signal8
Launch Terminal

Innoviva, Inc. (INVA)

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Innoviva, Inc. logo

Innoviva, Inc.

NASDAQ:INVAHealthcare
-0.42%$21.22
AH$21.22+0.00%vs close
Mkt Cap$1.53B
Float68.9M
O/S72.25M
Vol
$ Vol
RVOL
Inst Own-
SI10.6%
Earnings
Dilution
Innoviva, Inc. logoNASDAQ:INVA$21.22-0.42%
Phase Distribution
47 lead-sponsored trials·1 active·39 completed
Phase 129
Phase 210
Phase 2/32
Phase 34
Phase 41
Not applicable1
(28 more as collaborator)
Status Overview
Active, not recruiting1
Completed39
Stopped7

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    Phase 4 COPD and Suboptimal Inspiratory Flow Rate

    Revefenacin, Tiotropium

    Chronic Obstructive Pulmonary Disease

    Enrollment
    404
    Start
    Jan 2022
    Primary Completion
    Nov 2023
    Completion
    Nov 2023
    NCT05165485
  • Phase 3
    Completed

    Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

    ampreloxetine, Placebo

    Symptomatic Neurogenic Orthostatic Hypotension

    Enrollment
    195
    Start
    Jan 2019
    Primary Completion
    Jul 2021
    Completion
    Jul 2021
    NCT03750552
  • Phase 3
    Terminated

    Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

    ampreloxetine, Placebo

    Symptomatic Neurogenic Orthostatic Hypotension, MSA +2

    Enrollment
    203
    Start
    Feb 2019
    Primary Completion
    Nov 2021
    Completion
    Nov 2021
    NCT03829657
  • Phase 3
    Terminated

    Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

    ampreloxetine

    Symptomatic Neurogenic Orthostatic Hypotension

    Enrollment
    110
    Start
    Sep 2019
    Primary Completion
    Nov 2021
    Completion
    Nov 2021
    NCT04095793
  • Phase 3
    Active, not recruiting

    Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

    Ampreloxetine, Placebo

    Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy

    Enrollment
    102
    Start
    Jun 2023
    Primary Completion
    Jan 2026est.
    Completion
    Jan 2028est.
    NCT05696717
  • Phase 2/3
    Terminated

    Efficacy & Safety of TD-1473 in Ulcerative Colitis

    TD-1473 Dose A, TD-1473 Dose B

    Ulcerative Colitis (UC)

    Enrollment
    239
    Start
    Mar 2019
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT03758443
  • Phase 2/3
    Terminated

    TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

    TD-1473 Dose A, TD-1473 Dose B

    Ulcerative Colitis (UC)

    Enrollment
    46
    Start
    Jul 2020
    Primary Completion
    Oct 2021
    Completion
    Oct 2021
    NCT03920254
  • Phase 2
    Completed

    TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

    TD-1792, Vancomycin

    Staphylococcal Skin Infection

    Enrollment
    203
    Start
    Dec 2006
    Primary Completion
    May 2007
    Completion
    May 2007
    NCT00442832
  • Phase 2
    Completed

    An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.

    400 microgrammes GSK961081, 1200 microgrammes GSK961081

    Pulmonary Disease, Chronic Obstructive

    Enrollment
    45
    Start
    Apr 2008
    Primary Completion
    Oct 2008
    Completion
    Oct 2008
    NCT00674817
  • Phase 2
    Completed

    A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

    TD-9855, TD-9855

    Attention-Deficit/Hyperactivity Disorder, ADHD

    Enrollment
    295
    Start
    Dec 2011
    Primary Completion
    Oct 2013
    Completion
    Nov 2013
    NCT01458340
  • Phase 2
    Completed

    Phase 2 Study of TD-9855 to Treat Fibromyalgia

    TD-9855 Group 1, TD-9855 Group 2

    Fibromyalgia

    Enrollment
    392
    Start
    Nov 2012
    Primary Completion
    Jan 2014
    Completion
    Apr 2014
    NCT01693692
  • Phase 2
    Completed

    Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

    velusetrag dose 1, velusetrag dose 2

    Gastroparesis

    Enrollment
    34
    Start
    Dec 2012
    Primary Completion
    Dec 2013
    Completion
    Feb 2014
    NCT01718938
  • Phase 2
    Completed

    The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

    Velusetrag, Placebo

    Gastroparesis

    Enrollment
    233
    Start
    Dec 2014
    Primary Completion
    Jun 2017
    Completion
    Jun 2017
    NCT02267525
  • Phase 2
    Completed

    TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

    TD-9855, Placebo

    Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension +6

    Enrollment
    34
    Start
    Sep 2017
    Primary Completion
    Jul 2018
    Completion
    Nov 2018
    NCT02705755
  • Phase 2
    Terminated

    Efficacy and Safety of TD-1473 in Crohn's Disease

    Placebo, TD-1473

    Crohn's Disease

    Enrollment
    167
    Start
    Nov 2018
    Primary Completion
    Dec 2021
    Completion
    Dec 2021
    NCT03635112
  • Phase 2
    Completed

    Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response

    TD-8236, Placebo

    Asthma

    Enrollment
    24
    Start
    Nov 2019
    Primary Completion
    Aug 2020
    Completion
    Sep 2020
    NCT04150341
  • Phase 2
    Completed

    TD-0903 for ALI Associated With COVID-19

    TD-0903, Placebo

    Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19

    Enrollment
    235
    Start
    Jun 2020
    Primary Completion
    Apr 2021
    Completion
    Apr 2021
    NCT04402866
  • Phase 1
    Completed

    Succinate Salt Version of GSK961081 for Healthy Volunteers

    GSK961081, GSK961081 matching placebo

    Pulmonary Disease, Chronic Obstructive

    Enrollment
    18
    Start
    Nov 2007
    Primary Completion
    Jan 2008
    Completion
    Jan 2008
    NCT00550225
  • Phase 1
    Completed

    A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers

    GSK961081, GSK961081 matching placebo

    Pulmonary Disease, Chronic Obstructive

    Enrollment
    23
    Start
    Mar 2008
    Primary Completion
    May 2008
    Completion
    May 2008
    NCT00687700
  • Phase 1
    Completed

    Study of GSK961081 in Healthy Volunteer Subjects

    GSK961081 15mcg SD, GSK961081 3mcg SD

    Pulmonary Disease, Chronic Obstructive

    Enrollment
    46
    Start
    Nov 2005
    Primary Completion
    Oct 2006
    Completion
    Oct 2006
    NCT00887406
  • Phase 1
    Terminated

    A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects

    TD-8954, Placebo - saline

    Gastrointestinal Motility Disorder

    Enrollment
    16
    Start
    Sep 2012
    Primary Completion
    Nov 2012
    Completion
    Dec 2012
    NCT01644240
  • Phase 1
    Completed

    TD-1607 SAD Study in Healthy Subjects

    TD-1607, Placebo

    Serious Infections Due to Known or Suspected Gram-positive Pathogens

    Enrollment
    64
    Start
    Apr 2013
    Primary Completion
    Aug 2013
    Completion
    Oct 2013
    NCT01791049
  • Phase 1
    Completed

    TD-9855 Mass Balance Study

    TD-9855

    ADHD, Fibromyalgia

    Enrollment
    6
    Start
    Oct 2013
    Primary Completion
    Nov 2013
    Completion
    Dec 2013
    NCT01924143
  • Phase 1
    Completed

    TD-1607 MAD Study in Healthy Subjects

    TD-1607, Placebo

    Infections, Bacterial Infections

    Enrollment
    48
    Start
    Oct 2013
    Primary Completion
    Jun 2014
    Completion
    Jul 2014
    NCT01949103
  • Phase 1
    Completed

    TD-6450 SAD and MAD in Healthy Subjects

    TD-6450, Placebo

    Hepatitis C

    Enrollment
    111
    Start
    Feb 2014
    Primary Completion
    Aug 2014
    Completion
    Sep 2014
    NCT02022306

1-25 of 47

Search ClinicalTrials.gov for “Innoviva”